112 related articles for article (PubMed ID: 6095483)
21. Platelet aggregation and exposure of fibrinogen receptors by prostaglandin endoperoxide analogues.
Morinelli TA; Niewiarowski S; Kornecki E; Figures WR; Wachtfogel Y; Colman RW
Blood; 1983 Jan; 61(1):41-9. PubMed ID: 6293626
[No Abstract] [Full Text] [Related]
22. Identification of platelet inhibitor present in the melon (Cucurbitacea cucumis melo).
Altman R; Rouvier J; Weisenberger H
Thromb Haemost; 1985 Jun; 53(3):312-3. PubMed ID: 3931281
[TBL] [Abstract][Full Text] [Related]
23. Potentiation of endoperoxide analog-induced platelet aggregation by heparin.
Mehta P; Mehta J
Thromb Res; 1982 Jan 1-15; 25(1-2):91-9. PubMed ID: 7064132
[TBL] [Abstract][Full Text] [Related]
24. Alteration of platelet responses to metabolites of arachidonic acid by oral contraceptives.
Pan IQ; Hall ER; Wu KK
Br J Haematol; 1984 Oct; 58(2):317-23. PubMed ID: 6089860
[TBL] [Abstract][Full Text] [Related]
25. Elevation of platelet cyclic AMP level by thromboxane A2/prostaglandin H2 receptor agonists.
Ishikawa Y; Ogawa A
Thromb Res; 1991 Dec; 64(6):667-76. PubMed ID: 1665927
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade.
Ahn CH; Romstedt KJ; Wallace LJ; Miller DD; Feller DR
Biochem Pharmacol; 1988 Aug; 37(15):3023-33. PubMed ID: 3134894
[TBL] [Abstract][Full Text] [Related]
27. Intracellular levels of cyclic AMP and cyclic GMP differentially modify platelet aggregate size in human platelets activated with epinephrine or ADP.
Qi R; Ozaki Y; Satoh K; Yang LB; Asazuma N; Yatomi Y; Kume S
J Cardiovasc Pharmacol; 1996 Aug; 28(2):215-22. PubMed ID: 8856476
[TBL] [Abstract][Full Text] [Related]
28. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo.
Ogletree ML; Harris DN; Heran CL; Phillips MB; Michel IM; Goldenberg HJ
Eicosanoids; 1988; 1(2):85-91. PubMed ID: 2856188
[TBL] [Abstract][Full Text] [Related]
29. Stereo-dependent inhibition of human platelet function by the optical isomers of trimetoquinol.
Mayo JR; Navran SS; Huzoor-Akbar ; Miller DD; Feller DR
Biochem Pharmacol; 1981 Aug; 30(16):2237-41. PubMed ID: 7188564
[No Abstract] [Full Text] [Related]
30. Effects of prostaglandins, cAMP, and changes in cytosolic calcium on platelet aggregation induced by a thromboxane A2 mimic (U46619).
Yun JC; Ohman KP; Gill JR; Keiser H
Can J Physiol Pharmacol; 1991 May; 69(5):599-604. PubMed ID: 1650650
[TBL] [Abstract][Full Text] [Related]
31. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
32. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
Shaw LA; Batey AJ; Coker SJ
Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
[TBL] [Abstract][Full Text] [Related]
33. Arachidonate is an antagonist of platelet activation by the endoperoxide analog U46619.
Huang EM; Detwiler TC
Biochim Biophys Acta; 1982 Apr; 715(2):246-9. PubMed ID: 6803846
[No Abstract] [Full Text] [Related]
34. Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists.
Bush LR; Smith SG
Thromb Res; 1986 Nov; 44(3):377-89. PubMed ID: 2948294
[TBL] [Abstract][Full Text] [Related]
35. AH6809, a prostaglandin DP-receptor blocking drug on human platelets.
Keery RJ; Lumley P
Br J Pharmacol; 1988 Jul; 94(3):745-54. PubMed ID: 2460179
[TBL] [Abstract][Full Text] [Related]
36. Differential ability of agonists to express distinct pools of fibrinogen (GpIIb/IIIa) receptors which can mediate the aggregation of human platelets.
Watts IS; Keery RJ; Lumley P
Thromb Haemost; 1989 Nov; 62(3):955-61. PubMed ID: 2512682
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase.
Brüne B; Ullrich V
Mol Pharmacol; 1987 Oct; 32(4):497-504. PubMed ID: 2890093
[TBL] [Abstract][Full Text] [Related]
38. Antiplatelet actions of 2-(4-[1-(2-chlorophenyl) piperazinyl]) methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compound.
Ding YA; Chou TC; Chern JW; Yen MH
Thromb Res; 1995 Feb; 77(3):291-303. PubMed ID: 7740521
[TBL] [Abstract][Full Text] [Related]
39. A possible dual physiological role of extracellular ATP in the modulation of platelet aggregation.
Soslau G; Youngprapakorn D
Biochim Biophys Acta; 1997 Feb; 1355(2):131-40. PubMed ID: 9042333
[TBL] [Abstract][Full Text] [Related]
40. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
